ASYMMETRYBETA
Loading MRK...
Merck & Co Inc.MRKAs of 31 July 2026
Trailing (TTM)
Price to earnings·
Price to sales·
Price to book·
Price to op. cash flow·
Price to free cash flow·
Forward P/S (NTM)
Forward P/S (Y1)·
Forward P/S (Y2)·
Forward P/S (Y3)·
Forward P/S (Y4)·
Forward P/S (Y5)·
Forward P/E (NTM)
Forward P/E (Y1)·
Forward P/E (Y2)·
Forward P/E (Y3)·
Forward P/E (Y4)·
Forward P/E (Y5)·
Forward EV/EBIT (NTM)
Forward EV/EBIT (Y1)·
Forward EV/EBIT (Y2)·
Forward EV/EBIT (Y3)·
Forward EV/EBIT (Y4)·
Forward EV/EBIT (Y5)·
−300−1500+150+300
+17
PositiveNegative
Equilibrium
Valuation+50
CheapExpensive
Emotion+4
FearGreed
Fundamentals+37
WeakStrong
Valuation

Is Merck & Co Inc. undervalued or overvalued?

Where Merck & Co Inc. (MRK) trades across 21 valuation metrics, from price-to-sales and forward P/E to book and cash-flow multiples, each ranked against its own five-year history rather than a broad sector average, so you can see whether it is genuinely cheap or expensive on its own terms. Information, not advice.

Merck & Co Inc.MRKLast 5 years
V—E—F—A—
——
MRK priceasymmetryquant.com
A Asymmetry—
V Valuation—
E Emotion—
F Fundamentals—